PSP Research’s Apellis Pharmaceuticals APLS Stock Holding History

PSP Research’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21,866	Closed	-$549K	–	81
2025 Q4	$549K	Buy	+21,866	New	+$513K	0.48%	11

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

PSP Research's APLS Position: Q1 2026 in Review

PSP Research sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 21,866 shares — an estimated $549K sold.

PSP Research first reported a position in APLS in Q4 2025 and held it in 1 quarter. The position peaked at $549K in Q4 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

PSP Research reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
PSP Research sold 21,866 Apellis Pharmaceuticals shares in Q1 2026, an estimated $549K.
PSP Research first reported a position in Apellis Pharmaceuticals in Q4 2025 and held it in 1 quarter.
PSP Research's Apellis Pharmaceuticals position peaked at $549K in Q4 2025.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on PSP Research's 13F filing for Q1 2026, filed 17 Apr 2026.